Molecular Pharmacology Program

The Daniel Heller Lab

Share
Back to Top

Research

Daniel Heller, PhD
Daniel A. Heller, PhD

Cancer Nanomedicine Laboratory

We are a biomedical engineering laboratory that develops nanotechnologies to advance breakthroughs in the research, diagnosis, and treatment of cancer and allied diseases. We develop drug delivery technologies to target therapies to disease sites, advanced diagnostics to detect disease at earlier stages, and nanosensors to accelerate the discovery of new therapies. Please check out our recent innovations using the “View Lab Overview” button below…

View Lab Overview

Research Projects

VIDEO | 02:10

Inside My Lab: Daniel Heller

Go inside the lab of Daniel Heller from SKI’s Molecular Pharmacology Program.
Video Details
The Daniel Heller Lab
The Daniel Heller Lab

Featured News

Dan Heller
A Sensor Sniffs for Cancer, Using Artificial Intelligence

By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.
Man holding an IUD
To Detect Ovarian Cancer Early, Researchers Look to Nanotechnology

Could an implantable IUD help detect cancer early, when it is most curable? Scientists at the Sloan Kettering Institute are betting yes.
In the Lab
Two abstract paintings, one in color and one in black and white.
Science Meets Art to Build a Paintable Diagnostic Test for Cancer

A collaboration between a nanotechnology scientist and a visual artist leads to a promising diagnostic test and a new art form.

View All Featured News

Publications

M Kim, C Chen, P Wang, JJ Mulvey, Y Yang, C Wun, M Antman-Passig, H-B Luo, S Cho, K Long-Roche, LV Ramanathan, A Jagota, M Zheng, Y Wang, DA Heller*. “Machine-Learning-Based Detection of an Ovarian Cancer Disease Fingerprint from Serum via Quantum Defect-Modified Carbon Nanotube Arrays.” Nature Biomedical Engineering (2022). https://www.mskcc.org/news/sensor-sniffs-cancer-using-artificial-intelligence

D Tylawsky, H Kiguchi, J Vaynshteyn, J Gerwin, J Shah, T Islam, M Snuderl, M Greenblatt, D Boué, Y Shamay, P Raju*, DA Heller* “P-selectin Targeting Stimulates Caveolin-1-Mediated Endothelial Transcytosis in Medulloblastoma.” (2021) Preprint. https://doi.org/10.21203/rs.3.rs-658944/v1

Z Yaari, Y Yang, E Apfelbaum, C Cupo, A Settle, Q Cullen, W Cai, K Long Roche, DA Levine, M Fleisher, L Ramanathan, M Zheng, A Jagota, DA Heller*. ”A Perception-Based Machine-Perception Nanosensor Platform to Detect Cancer Biomarkers.” Science Advances 7 (2021) eabj0852. MSK News: https://www.mskcc.org/news/detect-ovarian-cancer-early-researchers-look-nanotechnology

TV Galassi, PV Jena, J Shah, G Ao, E Molitor, Y Bram, A Frankel, J Park, J Jessurun, DS Ory, A Haimovitz-Friedman, D Roxbury, J Mittal, M Zheng, R E Schwartz, DA Heller*. “An Optical Nanoreporter of Endolysosomal Lipid Accumulation Reveals Enduring Effects of Diet on Hepatic Macrophages In Vivo.” Science Translational Medicine 10 (2018) eaar2680.

Y Shamay, J Shah, DF Tschaharganeh, D Roxbury, J Budhathoki-Uprety, M Işık, A Mizrachi, K Nawaly, JL Sugarman, E Baut, MR Neiman, DC Johnson, R Sridharan, KL Chu, VK Rajasekhar, JD Chodera, SW Lowe, DA Heller*, “Quantitative Self-Assembly Prediction Yields Targeted Nanomedicines” Nature Materials (2018)

View All Publications

People

Daniel Heller, PhD

Daniel A. Heller, PhD

  • Biomedical engineer Daniel Heller is Head of the Cancer Nanotechnology Laboratory, which invents disruptive technologies to revolutionize the diagnosis and treatment of cancer and allied diseases.
  • PhD, University of Illinois at Urbana-Champaign
[email protected]
Email Address
646-888-3438
Office Phone
Download CV
PDF File

Members

Daniel A. Heller, PhD
Daniel A. Heller

Lab Head

Prakrit Jena, PhD
Prakrit Jena

Senior Research Scientist

Merav Antman-Passig
Merav Antman-Passig

Postdoctoral Research Fellow

Naxhije Berisha
Naxhije Berisha

CUNY Chemistry/Nanotechnology PhD Program Student

Chen Chen
Chen Chen

Tri-institutional PhD Program in Chemical Biology

Ron Feiner
Ron Feiner

Postdoctoral Research Fellow

Emma Grabarnik
Emma Grabarnik

Research Scholar

Declan Gwynne
Declan Gwynne

Senior Research Technician

Christopher Horoszko
Christopher Horoszko

Postdoctoral Research Fellow

Takeshi Irie
Takeshi Irie

Assistant Attending, Anesthesiology and Critical Care

Arianna Izawa-Ishiguro
Arianna Izawa-Ishiguro

Graduate Student

Mijin Kim
Mijin Kim

Postdoctoral Research Associate

Quincey LaPlant

Assistant Attending L1, Radiation Oncology

Magdalini Panagiotakopoulos
Magdalini Panagiotakopoulos

Postdoctoral Research Scholar

Stephen Ruiz
Stephen Ruiz

BCMB PhD Program Student

Janki Shah
Janki Shah

Lab Manager

Ramya Sridharan
Ramya Sridharan

PhD Pharmacology Program Weill Cornell, Memorial Sloan Kettering Cancer Center

Daniel Tylawsky
Daniel Tylawsky

Graduate Student (Weill Cornell Medicine; Pharmacology PhD Program)

Kristen Vogt
Kristen Vogt

Tri-institutional PhD Program in Chemical Biology

Laura Wilson
Laura Wilson

Administrative Assistant

Zvi Yaari, PhD
Zvi Yaari

Postdoctoral Research Fellow

Lab Alumni
Cynthia Almonte
Cynthia Almonte

Clinical Nurse

Elana Apfelbaum
Elana Apfelbaum

Research Technician

Hanan Baker
Hanan Baker

Graduate Student

Gavin Black
Gavin Black

Pharmacology PhD Program Student

Januka Budhathoki-Uprety, PhD
Januka Budhathoki-Uprety

Research Scholar

Christian Cupo
Christian Cupo

Research Technician

Rune Frederiksen
Rune Frederiksen

Research Fellow

Thomas Galassi
Thomas Galassi

Graduate Student

Jackson Harvey
Jackson Harvey

Research Scholar

Brian J. Joseph
Brian J. Joseph

Visiting Scientist

Hiro Kiguchi
Hiro Kiguchi

Pediatric Hematology/Oncology Fellow

Jaclyn Kubala
Jaclyn Kubala

Graduate Student

Pictured: Rachel Langenbacher
Rachel Langenbacher

Graduate Student

Mandana T. Manzari
Mandana T. Manzari

Research Scholar

Daniel Roxbury
Daniel Roxbury

Assistant Professor

Yosef Shamay
Yosef Shamay

Research Fellow

Maria Sirenko

Summer Undergraduate Research Student

Jasmine Wallas
Jasmine Wallas

Research Technician

Ryan Williams, PhD
Ryan Williams
Lab Affiliations

Achievements

  • American Institute for Medical and Biological Engineering (AIMBE) Fellow (2021)
  • Pharmacology Teaching and Mentoring Award, Weill Cornell Graduate School (2020)
  • American Cancer Society Research Scholar (2018)
  • NSF CAREER Award (2018)
  • Pershing Square Sohn Prize for Young Innovators in Cancer Research (2017)
Read more
  • NIH Director’s New Innovator Award (2012)
  • Damon Runyon Cancer Research Foundation Postdoctoral Fellowship (2010)
  • Beckman Institute Graduate Fellowship (2006)

Lab News & Events

Accolades

Team Recognitions

  • Congratulations to Naxhije Berisha - Tow Fellowship Awardee!
  • Congratulations to Dr. Mijin Kim - Kravis WiSE Postdoctoral Fellowship Winner!
  • Congratulations to Stephen Ruiz - awarded the MERIT Mandel Graduate Fellowship!

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Daniel A. Heller discloses the following relationships and financial interests:

  • Concarlo Holdings, LLC
    Provision of Services
  • Goldilocks Therapeutics Inc.
    Fiduciary Role/Position; Ownership / Equity Interests; Provision of Services (uncompensated)
  • LipidSense, Inc.
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Mediphage Bioceuticals, Inc.
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Nanorobotics, Inc.
    Ownership / Equity Interests
  • Nirova BioSense, Inc.
    Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: